Global Idiopathic Membranous Nephropathy (IMN) Market Study 2023-2032: Breakthrough Therapies Offer Hope for IMN Patients

DUBLIN, July 28, 2023 /PRNewswire/ -- The "Global Idiopathic Membranous Nephropathy (IMN) Industry Insights, 2023-2032" report has been added to ResearchAndMarkets.com's offering.

Advancements and Opportunities in Idiopathic Membranous Nephropathy (IMN) Treatment: A Comprehensive Market Research Report

Membranous Nephropathy (MN), also known as membranous glomerulopathy, is a rare kidney disease affecting the filters of the kidney. This condition results in increased protein in the urine, abnormal kidney function, and swelling. In primary or idiopathic MN, the disease is associated serologically with antibodies to known antigens, such as M-type phospholipase A2 receptor (PLA2R) or thrombospondin type-I domain-containing 7A (THSD7A). It is estimated that primary MN is responsible for approximately 75-80% of cases identified on kidney biopsy in adults. To diagnose primary MN, circulating autoantibodies, specifically anti-PLA2R and anti-THSD7A, are used as biomarkers with high specificity.

Market Size and Projections

In 2022, the United States recorded the highest market size for IMN, accounting for around USD 100 million. Looking forward to 2032, the IMN market in the US is expected to increase further. The prevalence of IMN is also on the rise globally, making it a significant concern for healthcare providers and pharmaceutical companies alike. The total prevalent cases of Idiopathic Membranous Nephropathy in the US, EU4 countries (Germany, France, Italy, Spain), the United Kingdom, Japan, and China reached approximately 380,000 cases in 2022 and are projected to increase during the forecasted period.

Current Treatment Landscape

The primary goal of IMN treatment is to achieve remission or reduce the amount of protein lost in the urine. Long-term treatment aims to prevent protein relapses and preserve kidney function. Immunosuppressive therapies like steroids, alkylating agents, and calcineurin inhibitors have been used to manage the condition. However, these therapies have limitations, including adverse reactions and higher relapse rates. Recent studies have shown promising outcomes with rituximab, an immunosuppressive drug, leading to increased attention and consideration for its use as a first-line treatment option.

Emerging Therapies and Market Potential

The IMN market is set to experience significant growth due to the emergence of novel therapies. Companies like Hoffmann-La Roche, MorphoSys, Cerium Pharmaceuticals, BeiGene, and GlaxoSmithKline are actively developing innovative treatments targeting IMN. Therapies like obinutuzumab, felzartamab, SNP-ACTH (1-39) Gel, zanubrutinib, and belimumab are under investigation and hold the potential to revolutionize IMN management.

Market Access and Reimbursement

As the cost of newly approved medications tends to be high, ensuring market access and reimbursement options becomes crucial. Patients often face challenges in accessing expensive treatments, and reimbursement decisions depend on factors like clinical efficacy, patient population size, and cost-effectiveness. Understanding country-specific accessibility issues is essential for pharmaceutical companies to overcome barriers and provide better patient access to novel therapies.

Conclusion

The market for Idiopathic Membranous Nephropathy is witnessing significant growth and advancements due to increased awareness and emerging therapies. The demand for effective treatments has led to the development of innovative drugs, offering hope to IMN patients. With primary MN affecting a substantial number of individuals globally, the need for improved treatment options is evident. Pharmaceutical companies and healthcare providers must collaborate to ensure better market access and reimbursement, enabling patients to benefit from the latest therapies. As research progresses and new treatments are introduced, patients with IMN can look forward to improved outcomes and a better quality of life.

Reasons to Buy

• The report will help develop business strategies by understanding the latest trends and changing treatment dynamics driving the IMN market.
• Insights on patient burden/disease prevalence and factors contributing to the change in the epidemiology of the disease during the forecast years.
• Understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, Spain) and the United Kingdom, Japan, and China.
• Identifying strong upcoming players in the market will help devise strategies to help get ahead of competitors.
• To understand Key Opinion Leaders' perspectives around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet need of the existing market so that the upcoming players can strengthen their development and launch strategy.

Key Topics Covered

1. Key Insights
2. Report Introduction
3. IMN Market Overview at a Glance
4. Executive Summary of IMN
5. Disease Background and Overview
6. Treatment and Management
7. Methodology
8. Epidemiology and Patient Population
9. Patient Journey
10. Emerging Drugs
11. IMN: 7MM + China Market Analysis
12. KOL Views
13. SWOT Analysis
14. Unmet needs
15. Market Access and Reimbursement
16. Appendix

A selection of companies mentioned in this report includes:

• Hoffmann-La Roche
• MorphoSys
• Cerium Pharmaceuticals
• BeiGene
• Reistone Biopharma
• Eternity Bioscience
• GlaxoSmithKline
• ValenzaBio
• ACELYRIN

For more information about this report visit https://www.researchandmarkets.com/r/qwy0ca

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets